Crystalline forms of therapeutic compounds and uses thereof
Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.
1. A crystalline form of Compound 1:
wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at about 8-9 degrees 2θ, about 10.5-11.5 degrees 2θ, and about 18-19 degrees 2θ.
2. The compound of claim 1 wherein the crystalline form is an anhydrate.
3. A process for preparing a crystalline form of claim 1 , comprising:
mixing amorphous Compound 1 and ethyl acetate; and
recovering crystalline form C.
4. A pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is suitable for topical administration.
6. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is suitable for injection.
7. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is suitable for delivery to the eye.
8. A kit comprising the pharmaceutical composition of claim 4 .